EA020523B9 - Производные хроменона с антиопухолевой активностью - Google Patents
Производные хроменона с антиопухолевой активностьюInfo
- Publication number
- EA020523B9 EA020523B9 EA201200618A EA201200618A EA020523B9 EA 020523 B9 EA020523 B9 EA 020523B9 EA 201200618 A EA201200618 A EA 201200618A EA 201200618 A EA201200618 A EA 201200618A EA 020523 B9 EA020523 B9 EA 020523B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chromenone derivatives
- tumour activity
- chromenone
- derivatives
- rhas
- Prior art date
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306017 | 2009-10-27 | ||
| PCT/GB2010/051788 WO2011051704A1 (en) | 2009-10-27 | 2010-10-25 | Chromenone derivatives with anti-tumour activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201200618A1 EA201200618A1 (ru) | 2012-12-28 |
| EA020523B1 EA020523B1 (ru) | 2014-11-28 |
| EA020523B9 true EA020523B9 (ru) | 2015-01-30 |
Family
ID=43085922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200618A EA020523B9 (ru) | 2009-10-27 | 2010-10-25 | Производные хроменона с антиопухолевой активностью |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2474147T3 (es) | 2008-05-30 | 2014-07-08 | Amgen, Inc | Inhibidores de PI3 cinasa |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| PE20151979A1 (es) | 2013-01-23 | 2016-01-15 | Astrazeneca Ab | Compuestos quimicos |
| RU2666999C2 (ru) * | 2013-03-04 | 2018-09-13 | Астразенека Аб | Комбинированное лечение |
| MX2016016538A (es) | 2014-06-13 | 2017-05-01 | Gilead Sciences Inc | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. |
| US9499523B2 (en) | 2014-06-13 | 2016-11-22 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| AU2015274696B2 (en) | 2014-06-13 | 2018-09-27 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| KR20170010063A (ko) | 2014-06-13 | 2017-01-25 | 길리애드 사이언시즈, 인코포레이티드 | 포스파티딜이노시톨 3-키나제 억제제 |
| EA201692249A1 (ru) | 2014-06-13 | 2017-05-31 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| CN108349946B (zh) * | 2015-10-09 | 2021-05-18 | 詹森药业有限公司 | 作为PI3Kβ抑制剂的喹喔啉和吡啶并吡嗪衍生物 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20210141214A (ko) * | 2020-05-15 | 2021-11-23 | 제이투에이치바이오텍 (주) | 3원환 화합물 및 이의 의약 용도 |
| US20240166617A1 (en) * | 2021-02-01 | 2024-05-23 | Geode Therapeutics Inc. | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof |
| MX2023013082A (es) * | 2021-05-03 | 2024-01-08 | Petra Pharma Corp | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades. |
| TW202309003A (zh) * | 2021-05-03 | 2023-03-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| KR20240014065A (ko) * | 2021-05-27 | 2024-01-31 | 페트라 파마 코포레이션 | 암의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| US20250084048A1 (en) * | 2021-10-07 | 2025-03-13 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| WO2024081904A1 (en) * | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| CN119431297A (zh) * | 2023-08-02 | 2025-02-14 | 郑州同源康医药有限公司 | 稠环类化合物及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004016607A1 (en) * | 2002-08-16 | 2004-02-26 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6027A (en) * | 1849-01-09 | Rotary blacksmith s twyer | ||
| JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| CA2081577A1 (en) | 1990-06-20 | 1991-12-21 | Ronald B. Gammill | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288138B6 (sk) | 1999-02-10 | 2013-11-04 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| AU2001230426C1 (en) | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| AR054438A1 (es) * | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
| EP1957475A1 (en) | 2005-10-21 | 2008-08-20 | Merz Pharma GmbH & Co.KGaA | Chromenones and their use as modulators of metabotropic glutamate receptors |
| SI2004654T1 (sl) * | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2112145A1 (en) | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
| WO2010134082A1 (en) | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2010
- 2010-10-22 US US12/909,968 patent/US8399460B2/en active Active
- 2010-10-25 BR BR112012010124A patent/BR112012010124B8/pt not_active IP Right Cessation
- 2010-10-25 HR HRP20150146TT patent/HRP20150146T1/hr unknown
- 2010-10-25 AU AU2010311107A patent/AU2010311107B9/en not_active Ceased
- 2010-10-25 MX MX2012005027A patent/MX2012005027A/es active IP Right Grant
- 2010-10-25 JP JP2012535931A patent/JP5657010B2/ja not_active Expired - Fee Related
- 2010-10-25 IN IN3328DEN2012 patent/IN2012DN03328A/en unknown
- 2010-10-25 RS RS20150090A patent/RS53813B1/sr unknown
- 2010-10-25 EA EA201200618A patent/EA020523B9/ru not_active IP Right Cessation
- 2010-10-25 NZ NZ599457A patent/NZ599457A/en not_active IP Right Cessation
- 2010-10-25 MY MYPI2012001831A patent/MY179833A/en unknown
- 2010-10-25 CN CN201080060262.7A patent/CN102712615B/zh not_active Expired - Fee Related
- 2010-10-25 PH PH1/2012/500804A patent/PH12012500804A1/en unknown
- 2010-10-25 PE PE2012000578A patent/PE20130149A1/es active IP Right Grant
- 2010-10-25 EP EP10769052.1A patent/EP2493870B1/en active Active
- 2010-10-25 SI SI201030875T patent/SI2493870T1/sl unknown
- 2010-10-25 PL PL10769052T patent/PL2493870T3/pl unknown
- 2010-10-25 CN CN201410654983.0A patent/CN104447657B/zh not_active Expired - Fee Related
- 2010-10-25 DK DK10769052.1T patent/DK2493870T3/en active
- 2010-10-25 UA UAA201206000A patent/UA107474C2/uk unknown
- 2010-10-25 ME MEP-2015-21A patent/ME02050B/me unknown
- 2010-10-25 PT PT10769052T patent/PT2493870E/pt unknown
- 2010-10-25 CA CA2776994A patent/CA2776994C/en active Active
- 2010-10-25 KR KR1020127012933A patent/KR101738195B1/ko not_active Expired - Fee Related
- 2010-10-25 ES ES10769052T patent/ES2530943T3/es active Active
- 2010-10-25 WO PCT/GB2010/051788 patent/WO2011051704A1/en not_active Ceased
- 2010-10-26 AR ARP100103937 patent/AR078786A1/es active IP Right Grant
- 2010-10-27 TW TW099136762A patent/TWI483939B/zh not_active IP Right Cessation
- 2010-10-27 UY UY32978A patent/UY32978A/es not_active Application Discontinuation
- 2010-10-27 SA SA110310808A patent/SA110310808B1/ar unknown
-
2012
- 2012-04-15 IL IL219191A patent/IL219191A0/en not_active IP Right Cessation
- 2012-04-25 CL CL2012001056A patent/CL2012001056A1/es unknown
- 2012-04-26 CO CO12068977A patent/CO6541528A2/es active IP Right Grant
- 2012-04-27 HN HN2012000889A patent/HN2012000889A/es unknown
- 2012-04-27 CR CR20120217A patent/CR20120217A/es unknown
- 2012-04-27 CU CU2012000069A patent/CU20120069A7/es unknown
- 2012-04-27 NI NI201200081A patent/NI201200081A/es unknown
- 2012-04-27 EC ECSP12011838 patent/ECSP12011838A/es unknown
- 2012-04-27 GT GT201200126A patent/GT201200126A/es unknown
- 2012-04-27 DO DO2012000124A patent/DOP2012000124A/es unknown
-
2013
- 2013-02-13 US US13/765,850 patent/US8673906B2/en active Active
-
2014
- 2014-01-24 US US14/163,105 patent/US9029374B2/en active Active
- 2014-11-20 JP JP2014235289A patent/JP5872016B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-12 SM SM201500036T patent/SMT201500036B/xx unknown
- 2015-02-13 CY CY20151100157T patent/CY1116143T1/el unknown
- 2015-04-08 US US14/681,244 patent/US20160060240A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,633 patent/US9718800B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004016607A1 (en) * | 2002-08-16 | 2004-02-26 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| US20060276470A1 (en) * | 2002-08-16 | 2006-12-07 | Jackson Shaun P | Inhibition of phsphoinostide 3-dinase beta |
Non-Patent Citations (1)
| Title |
|---|
| GRIFFIN R.J. ET AL.: "Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 48, no. 2, 27 January 2005 (2005-01-27), pages 569-585, XP002381166, ISSN: 0022-2623, DOI:10.1021/JM049526A, Abstract; Table 2 (A) and Conclusions * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA020523B9 (ru) | Производные хроменона с антиопухолевой активностью | |
| MX2013011931A (es) | Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer. | |
| MD20140086A2 (ro) | Derivaţi macrociclici pentru tratamentul bolilor proliferative | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| IL217378A (en) | History of oxazin, containing pharmaceuticals and their use in the preparation of drugs for the treatment of neurological disorders | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| IN2014DN09434A (show.php) | ||
| TN2014000175A1 (en) | Novel purine derivatives and their use in the treatment of disease | |
| MX2012008328A (es) | Derivados de pirazina. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| MX2015004362A (es) | Derivados de ketamina. | |
| MX340574B (es) | Imidazo pirazinas. | |
| TW201129560A (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| BR112014009580A2 (pt) | composição farmacêutica de omeprazol | |
| WO2014043252A3 (en) | Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application | |
| EA024038B9 (ru) | Производные нитрила, их использование в фармацевтических целях и в композициях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ |